title: A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: a Southwest Oncology Group Study.
abstract: Cisplatin was given intravenously to 35 evaluable patients with unresectable malignant mesothelioma on Southwest Oncology Group (SWOG) Study 8418. Five patients (14.3%) achieved partial response with median response duration of six months (range 2-12 months); eleven patients (31.4%) had stable disease of median duration of 5.5. months (range 2-21 months). Median survival for all patients was 7.5 months, 9 months for responders. Toxicity was as expected except that 12 patients (34.2%) discontinued cisplatin because of side effects. Cisplatin has moderate activity in mesothelioma and further studies with platinum analogues should be pursued.
authors.affiliation: Allegheny General Hospital, Seattle.
authors.forename: B L
authors.initials: BL
authors.lastname: Zidar
authors.forename: S
authors.initials: S
authors.lastname: Green
authors.forename: H I
authors.initials: HI
authors.lastname: Pierce
authors.forename: R W
authors.initials: RW
authors.lastname: Roach
authors.forename: S P
authors.initials: SP
authors.lastname: Balcerzak
authors.forename: L
authors.initials: L
authors.lastname: Militello
mesh_terms: D000328:Adult; D000368:Aged; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008654:Mesothelioma / Q000188:drug therapy* / Q000401:mortality; D008875:Middle Aged; D015206:Southwestern United States
chemical_list: D002945:Cisplatin